Response Selection in Visual Search: The Influence of Response Compatibility of Nontargets.

this article should be addressed to Peter A. Starreveld, Department of Cognitive Psychology, Vrije Universiteit, Van der Boechorststraat 1, 1081 BT Amsterdam, the Netherlands. E-mail: [email protected] Journal of Experimental Psychology: Copyright 2004 by the American Psychological Association, Inc. Human Perception and Performance 2004, Vol. 30, No. 1, 56 --78 0096-1523/04/$12.00 DOI: 10.1037/0096-1523.30.1.56 56 As discussed previously, flat slopes of search functions are interpreted as evidence showing that distractor elements in the corresponding experiments were only preattentively processed. Because identification of a display element involves attentive processing, two-stage theories of visual search predict that the identities of distractors should not affect the search time for a target in any search task in which flat search slopes are obtained. In the present study, this prediction was put to the tes

Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism

A trans-National Institutes of Health initiative, Nutrition and Dietary Supplement Interventions for Inborn Errors of Metabolism (NDSI-IEM), was launched in 2010 to identify gaps in knowledge regarding the safety and utility of nutritional interventions for the management of inborn errors of metabolism (IEM) that need to be filled with evidence-based research. IEM include inherited biochemical disorders in which specific enzyme defects interfere with the normal metabolism of exogenous (dietary) or endogenous protein, carbohydrate, or fat. For some of these IEM, effective management depends primarily on nutritional interventions. Further research is needed to demonstrate the impact of nutritional interventions on individual health outcomes and on the psychosocial issues identified by patients and their families. A series of meetings and discussions were convened to explore the current United States’ funding and regulatory infrastructure and the challenges to the conduct of research for nutritional interventions for the management of IEM. Although the research and regulatory infrastructure are well-established, a collaborative pathway that includes the professional and advocacy rare disease community and federal regulatory and research agencies will be needed to overcome current barriers

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Cognitive Restoration from Nature Across Multiple Exposure Types - A Meta-Analysis Delineating the Effects of Test Order and Affect

Interactions with natural environments and nature-related stimuli have been found to be beneficial to cognitive performance, in particular on executive cognitive tasks with high demands on directed attention processes. However, results vary across different studies. The aim of the present study was to perform a meta-analysis of all our published and unpublished studies testing the effect of different interactions with nature versus urban/built control environments, on an executive test with high demands on directed attention: the backwards digit span (BDS) task. Specific aims were to evaluate the effect of nature versus urban environment interactions on BDS across different exposure types (e.g. being in real environments, or viewing videos, images, or listening to sounds) and disentangle the effects of testing order (i.e. practice with repeated testing) and the role of affective changes on BDS performance. We also reviewed the literature and compared and contrasted our meta-analysis with results from other studies. Results from our meta-analysis comprising 12 studies (N=567 participants) showed significant environment-by-time interactions with beneficial effects of nature compared to urban environments on BDS performance. This effect was magnified after parceling out initial practice effects on the BDS. Changes in positive or negative affect did not mediate the beneficial effects of nature on BDS performance. These results mirrored effects that we reviewed from outside of our laboratories. Uncontrolled and confounding order effects may explain some of the inconsistent findings in the literature. In all, these results highlight the robustness of the effects of natural environments on cognition when confounding order effects have been considered, and also provide a more nuanced account of when a nature intervention will be most effective

Cognitive Restoration from Nature Across Multiple Exposure Types - A Meta-Analysis Delineating the Effects of Test Order and Affect

Interactions with natural environments and nature-related stimuli have been found to be beneficial to cognitive performance, in particular on executive cognitive tasks with high demands on directed attention processes. However, results vary across different studies. The aim of the present study was to perform a meta-analysis of all our published and unpublished studies testing the effect of different interactions with nature versus urban/built control environments, on an executive test with high demands on directed attention: the backwards digit span (BDS) task. Specific aims were to evaluate the effect of nature versus urban environment interactions on BDS across different exposure types (e.g. being in real environments, or viewing videos, images, or listening to sounds) and disentangle the effects of testing order (i.e. practice with repeated testing) and the role of affective changes on BDS performance. We also reviewed the literature and compared and contrasted our meta-analysis with results from other studies. Results from our meta-analysis comprising 12 studies (N=567 participants) showed significant environment-by-time interactions with beneficial effects of nature compared to urban environments on BDS performance. This effect was magnified after parceling out initial practice effects on the BDS. Changes in positive or negative affect did not mediate the beneficial effects of nature on BDS performance. These results mirrored effects that we reviewed from outside of our laboratories. Uncontrolled and confounding order effects may explain some of the inconsistent findings in the literature. In all, these results highlight the robustness of the effects of natural environments on cognition when confounding order effects have been considered, and also provide a more nuanced account of when a nature intervention will be most effective

sj-pdf-1-mpp-10.1177_23814683231202716 – Supplemental material for Adaptive COVID-19 Mitigation Strategies

Supplemental material, sj-pdf-1-mpp-10.1177_23814683231202716 for Adaptive COVID-19 Mitigation Strategies by Erinn C. Sanstead, Zongbo Li, Shannon B. McKearnan, Szu-Yu Zoe Kao, Pamela J. Mink, Alisha Baines Simon, Karen M. Kuntz, Stefan Gildemeister and Eva A. Enns in MDM Policy & Practice</p

What we talk about when we talk about durable viral suppression

As policies built on “Undetectable = Untransmittable” become more popular, use of durable viral suppression (DVS) as an outcome in analyses is increasing. We identified a case series of recent HIV-related publications that study the DVS outcome. The majority did not distinguish between a definition of DVS and the operationalization of that definition. Clearer discussion of DVS, including a formal definition, is needed to ensure better comparability across studies and ultimately better public health outcomes